Natera v. NeoGenomics: Causal Nexus and the Equity of a Two-Player Market
The Federal Circuit affirms a preliminary injunction barring a competing cancer-recurrence assay, sharpening how courts trace irreparable harm to the patented method through the causal-nexus requirement.